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**Additional file 1.** Full Study Protocol.
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The trial is funded by the *Instituto de Salud Carlos III* from the Spanish Ministry of Science and Innovation extraordinary research call on SARS-COV-2 and COVID-19. Project code: COV20/286 (approved on April 17^th^, 2020). The funding body has no role in the design of the study, collection of data and in writing the manuscript.

All data will be available to the research collaborators. Decision to publish rests solely with the researchers. The full data set will be made publicly available not later than six months after trial completion.

On April 2^nd^, 2020, a short trial proposal was approved by the *Comité de Ética en Investigación* of the Hospital Clínic of Barcelona to allow the start of the clinical trial procedures in the COVID-19 emergency situation (trial code HCB/2020/0382, meeting reference 9/2020_Extraordinària). The full trial protocol was approved as an amendment by the same committee on the ordinary meeting of May 14^th^, 2020.

The clinical trial was authorized by the Spanish Agency of Drugs and Medical Products (AEMPS) on April 8^th^, 2020 (authorization tracking code FEPZKWTD4D), and the agency approved the full protocol on May 22^nd^, 2020 (authorization tracking code FBVJZBZ766).

Informed consent will be obtained from all participants.
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